fda compounding semaglutide crackdown news today The FDA's GLP-1 Continues: What to Know The FDA's Decision to Ban

[DOI] [PMC free article] [PubMed] [Google Scholar] 109.Gibbons CH, Freeman R

Pomegranate Health and GobyMeds name pharmacy partners with cleaner records

Repeatedly injecting into the same site can cause increased pain and bruising

Whether youre using insurance for branded GLP-1s or prefer an all-in-one solution with medication included, theres a path for you

unfortunately, they have not proved effective in treating sepsis [78]

headache was the most common side effect, and exploratory breast-milk measures suggested rapid clearance Pre-registered experiment gave 78 healthy volunteers inert air framed as nitrous oxide Context alone increased altered states, ego dissolution, dissociation, and side effects, despite no active drug Suggestibility and absorption helped predict who was most responsive, sharpening how we think about set, setting, placebo, and nocebo effects - Two randomised trials tested oral prolonged-release ketamine: a Phase 1 crossover study (n=26) and a Phase 2 placebo-controlled TRD trial (n=122) The tablet caused far less dissociation and cardiovascular change than intranasal esketamine But it missed the main day-21 depression endpoint, showing that better tolerability does not automatically mean better efficacy ;: June brought a striking early GH001 signal in postpartum depression, a reminder that context can produce psychedelic-like effects without a drug, and a ketamine formulation trial where better tolerability did not translate into a clear antidepressant win